Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + tariquidar
- Development stage
- Phase 2
- Lead developer
- QLT
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + tariquidar is an investigational combination therapy consisting of the chemotherapeutic agent docetaxel and the third-generation P-glycoprotein (Pgp) inhibitor tariquidar. Docetaxel is a taxane-class antineoplastic that stabilizes microtubules, thereby inhibiting cell division and inducing apoptosis in cancer cells. Tariquidar is a potent, noncompetitive inhibitor of P-glycoprotein, a drug efflux transporter associated with multidrug resistance in cancer. By inhibiting Pgp, tariquidar increases intracellular concentrations of chemotherapeutic agents like docetaxel in resistant tumor cells. This combination has been studied primarily for its potential to overcome multidrug resistance in solid tumors such as non-small cell lung cancer and ovarian cancer[1][2][4]. Clinical studies have shown that this regimen can be administered safely with manageable toxicity profiles; pharmacodynamic data confirm effective inhibition of Pgp-mediated drug efflux by tariquidar[1][2].
- Other names
- docetaxel and tariquidarDTX + TRQ
02
Targets
ABCB1 (P-glycoprotein)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + tariquidar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + tariquidar.